ChiCTR2100052226 版本V1.1 版本创建时间2021/10/23 12:12:33 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2100052226 

最近更新日期:

Date of Last Refreshed on:

2021-10-23 09:42:33 

注册时间:

Date of Registration:

2021-10-23 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

重度创伤后机体自身肝素化对临床合理输血的影响

Public title:

Influence of autoheparinization on clinical rational blood transfusion after severe trauma

注册题目简写:

English Acronym:

研究课题的正式科学名称:

重度创伤后机体自身肝素化对临床合理输血的影响

Scientific title:

Influence of autoheparinization on clinical rational blood transfusion after severe trauma

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

田艳 

研究负责人:

田艳 

Applicant:

TianYan 

Study leader:

TianYan 

申请注册联系人电话:

Applicant telephone:

13616029012

研究负责人电话:

Study leader's
telephone:

13616029012

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

tianyan331526@163.com

研究负责人电子邮件:

Study leader's E-mail:

tianyan331526@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中国福建省厦门市集美区盛光路566号厦门医学院附属第二医院

研究负责人通讯地址:

中国福建省厦门市集美区盛光路566号厦门医学院附属第二医院

Applicant address:

The Second Affiliated Hospital of Xiamen Medical College, 566 Shengguang Road, Jimei District, Xiamen city, Fujian Province, China

Study leader's address:

The Second Affiliated Hospital of Xiamen Medical College, 566 Shengguang Road, Jimei District, Xiamen city, Fujian Province, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

厦门医学院附属第二医院

Applicant's institution:

The Second Affiliated Hospital of Xiamen Medical College

研究负责人所在单位:

Affiliation of the Leader:

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

2017015

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

厦门医学院附属第二医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Second Affiliated Hospital of Xiamen Medical College

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

田艳

Contact Name of the ethic committee:

Medical Ethics Committee of the Second Affiliated Hospital of Xiamen Medical College

伦理委员会联系地址:

中国福建省厦门市集美区盛光路566号厦门医学院附属第二医院

Contact Address of the ethic committee:

The Second Affiliated Hospital of Xiamen Medical College, 566 Shengguang Road, Jimei District, Xiamen city, Fujian Province, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

中国福建省厦门市集美区盛光路566号厦门医学院附属第二医院

Primary sponsor:

The Second Affiliated Hospital of Xiamen Medical College, 566 Shengguang Road, Jimei District, Xiamen city, Fujian Province, China

研究实施负责(组长)单位地址:

中国福建省厦门市集美区盛光路566号厦门医学院附属第二医院

Primary sponsor's address:

The Second Affiliated Hospital of Xiamen Medical College, 566 Shengguang Road, Jimei District, Xiamen city, Fujian Province, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

福建

市(区县):

Country:

China

Province:

Fujian

City:

单位(医院):

厦门医学院附属第二医院

具体地址:

集美区盛光路566号

Institution
hospital:

The Second Affiliated Hospital of Xiamen Medical College

Address:

566 Shengguang Road, Jimei District

经费或物资来源:

福建省卫计委

Source(s) of funding:

Fujian Provincial Health and Family Planning Commission

研究疾病:

重度创伤  

Target disease:

Severe trauma

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

通过hmTEG法筛选存在自身肝素化的重度创伤患者,根据是否用鱼精蛋白干预分为干预组和未干预组,分别检测ATⅢ、抗Xa活性和PF4三指标的改变以验证内源性类肝素物质的产生和变化规律。统计分析两组患者临床用血情况,探讨自身肝素化的有效鉴定对临床输血的影响。  

Objectives of Study:

Severe trauma patients with autoheparinization were screened by hmTEG method, and were divided into intervention group and non-intervention group according to whether protamine was used for intervention. Changes of AT ⅲ, anti-XA activity and PF4 were detected to verify the production and change rule of endogenous heparin-like substances. The clinical blood use of the two groups was statistically analyzed to explore the effect of effective identification of autoheparinization on clinical blood transfusion.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

筛查研究对象,针对6个损伤部位(头颈、胸部、腹部、脊柱、四肢和体表)分为1-5分,然后对三个损伤最重的脏器评分进行平方其平方之和即为ISS分值,分值范围0-75分。根据损伤严重度评分(ISS)评分≥16为重度创伤患者。收集2017年9月后的重度创伤病例,在排除医嘱未用肝素类药物前提下,用hmTEG检测是否存在内源性类肝素物质,判断标准:肝素酶R值-普通杯R值>5min。确定有内源性类肝素物质存在的患者分两组,A组(鱼精蛋白干预组)和B组(未用鱼精蛋白干预组),各24例。

Inclusion criteria

The 6 injury sites (head and neck, chest, abdomen, spine, limbs and body surface) were divided into 1-5 points. Then, the score of the three most damaged organs was squared, which was the sum of the squares, which was the ISS score, and the score ranged from 0 to 75 points. Patients with severe trauma were classified as having injury severity Scale (ISS) score ≥16. Severe trauma cases after September 2017 were collected, and the presence of endogenous heparin-like substances was detected by hmTEG on the condition that heparin drugs were not used as prescribed by doctors. The judgment criteria were as follows: Heparinase R-ordinary cup R-value >5min. The patients confirmed the presence of endogenous heparin-like substances were divided into two groups, group A (protamine intervention group) and group B (no protamine intervention group), with 24 patients each.

排除标准:

两组患者排除严重肝肾疾病、血液病等慢性疾病导致凝血障碍者,在年龄、性别、体质量、ISS 评分上差异无统计学意义(P > 0.05),具有可比性。采用过敏原检测无鱼类过敏者入选。

Exclusion criteria:

Patients with coagulation disorders caused by chronic diseases such as severe liver and kidney diseases and hematologic diseases were excluded from the two groups, and there was no significant difference in age, gender, body weight and ISS score (P > 0.05), indicating comparability. Those without fish allergy detected by allergen were selected.

研究实施时间:

Study execute time:

From 2018-09-23 00:00:00 To 2022-10-01 00:00:00  

征募观察对象时间:

Recruiting time:

From 2018-09-23 00:00:00 To 2021-10-01 00:00:00

干预措施:

Interventions:

组别:

Group 1

样本量:

24

Group:

Group 1

Sample size:

干预措施:

鱼精蛋白干预

干预措施代码:

Intervention:

Protamine is given intravenously

Intervention code:

组别:

Group 2

样本量:

24

Group:

Group 2

Sample size:

干预措施:

未用鱼精蛋白干预组

干预措施代码:

Intervention:

No intervention

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

福建 

市(区县):

 

Country:

China

Province:

Fujian

City:

单位(医院):

厦门医学院附属第二医院 

单位级别:

三甲 

Institution
hospital:

The Second Affiliated Hospital of Xiamen Medical College

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

血栓弹力图结果

指标类型:

主要指标

Outcome:

Thromboelastogram results

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

AT III

指标类型:

主要指标

Outcome:

AT III

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

抗Xa活性

指标类型:

主要指标

Outcome:

Anti Xa activity

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

PF4

指标类型:

主要指标

Outcome:

PF4

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 72 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

筛查研究对象,针对6个损伤部位(头颈、胸部、腹部、脊柱、四肢和体表)分为1-5分,然后对三个损伤最重的脏器评分进行平方其平方之和即为ISS分值,分值范围0-75分。根据损伤严重度评分(ISS)评分≥16为重度创伤患者。收集2017年9月后的重度创伤病例,在排除医嘱未用肝素类药物前提下,用hmTEG检测是否存在内源性类肝素物质,判断标准:肝素酶R值-普通杯R值>5min。确定有内源性类肝素物质存在的患者分两组,A组(鱼精蛋白干预组)和B组(未用鱼精蛋白干预组),各24例。排除标准:两组患者排除严重肝肾疾病、血液病等慢性疾病导致凝血障碍者,在年龄、性别、体质量、ISS 评分上差异无统计学意义(P > 0.05),具有可比性。采用过敏原检测无鱼类过敏者入选。

Randomization Procedure (please state who generates the random number sequence and by what method):

The 6 injury sites (head and neck, chest, abdomen, spine, limbs and body surface) were divided into 1-5 points. Then, the score of the three most damaged organs was squared, which was the sum of the squares, which was the ISS score, and the score ranged from 0 to 75 points. Patients with

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

中国知网

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

CNKI(China National Knowledge Infrastructure)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表(Case Record Form, CRF)

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form, CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2021-10-23 09:42:28